Imatinib (imatinib mesylate, STI-571, Gleevec) is a selective BCR-ABL tyrosine kinase inhibitor that has been used as a highly effective chemoagent for treating chronic myelogenous leukemia. However, the initial response to imatinib is often followed by the recurrence of a resistant form of the disease, which is major obstacle to many therapeutic modalities. The aim of this study was to identify the gene expression signatures that confer resistance to imatinib. A series of four resistant K562 sublines was established with different imatinib dosage (200, 400, 600 and 800 nM) and analyzed using microarray technology. The transcripts of the genes showing universal or dose-dependent expression changes across the resistant sublines were identified. The gene sets associated with the imatinib-resistance were also identified using gene set enrichment analysis. In the resistant K562 sublines, the transcriptionand apoptosis-related expression signatures were upregulated, whereas those related to the protein and energy metabolism were downregulated. Several genes identified in this study such as IGF1 and RAB11A have the potential to become surrogate markers useful in a clinical evaluation of imatinibresistant patients without BCR-ABL mutation. The expression signatures identified in this study provide insights into the mechanism of imatinib-resistance and are expected to facilitate the development of an effective diagnostic and therapeutic strategy.
Introduction
Imatinib (imatinib mesylate, STI-571, Gleevec) is a selective tyrosine kinase inhibitor that has been successfully used to treat chronic myloid leukemia (CML). Targeting to BCR-ABL fusion kinase, the primary pathogenic molecule for disease, imatinib achieved remarkable remission rates up to B80%, especially for initial phase of CML. 1 However, relapse after the initial hematologic and cytologenetic response frequently occurred in late-stage disease. 2 This suggests that BCR-ABL targeted therapy can be hindered by the acquisition of resistance, which seriously reduces the clinical efficacy of imatinib.
Transcriptional amplification or point mutations in the tyrosine kinase domain of BCR-ABL have been frequently observed in resistant clinical cases or in vitro cell models. [3] [4] [5] Although these changes are considered almost sufficient cause of obtaining imatinib-resistance, previous studies have also shown that resistance can occur without any apparent amplification or point mutations in BCR-ABL. [6] [7] [8] In addition, the overexpression of multidrug resistance genes has been suggested to confer the resistance to imatinib. 9, 10 These reports suggest that heterogeneous mechanisms might be responsible for imatinib-resistance. To identify key genetic elements responsible for imatinib-resistance, various approaches including global gene expression analysis using a microarray have been used. 7, 11, 12 With the aim of deciphering gene expression signatures associated with imatinib-resistance, this study focused on the transcripts showing biologically relevant expression changes by examining the expression profiles across four imatinib-resistant sublines established with different imatinib dosage and primary CML cases. We present expression profiles and candidate signal pathways associated with imatinib-resistance through improved bioinformatical approaches including gene set enrichment analysis.
Materials and methods

Establishment of imatinib-resistant cell lines
The resistance to imatinib was established by exposing the erythroid leukemic K562 cell lines to increasing imatinib concentrations by 50 nM every 2 weeks. During the culture with imatinib, a series of four resistant sublines exposed to various imatinib concentrations (200, 400, 600 and 800 nM) were established. Any mutations of the BCR-ABL kinase domain were screened as described previously. 4 In addition, the expression level of BCR-ABL kinase was examined using realtime reverse transcriptase-polymerase chain reaction (PCR) with the same primers used for mutation analysis and for human glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as internal control.
RNA preparation and hybridization
Total RNA of K562 and imatinib-resistant sublines was isolated with Trizol (Invitrogen, Carlsbad, CA) according to the manufacturer's instruction. The quantity and quality of extracted RNA was assessed by using a Bioanalyzer 2100 (Agilent Technologies, Waldbronn, Germany). Applied Biosystems Human Genome Survey Microarray Version 2.0 representing a set of B30 000 human genes were used to analyze the expression profiles of the five cell lines (parental sensitive K562 and four resistant sublines). Digoxigenin-UTP-labeled cRNA was generated and linearly amplified from 5 mg of total RNA using Applied Biosystems Chemiluminescent RT-IVT Labeling Kit V2.0. Array hybridization, Chemiluminescence detection, image acquisition and analysis were performed using Applied Biosystems Chemiluminescence Detection Kit and Applied Biosystems 1700 Chemiluminescent Microarray Analyzer according to the manufacturer's protocol. The hybridization reaction was triplicated per sample.
Data processing
Image of each array hybridization was collected using the 1700 analyzer, which is equipped with high-resolution, large-format CCD camera, including two 'short' chemiluminescent images with 5 s exposure length for gene expression analysis, two fluorescent images for feature finding and spot normalization and 2QC images for spectrum cross-talk correction. Images were auto-gridded and the chemiluminescent signals were quantified. After the background subtraction, spot intensity data were normalized by using variance stabilization and normalization method. 13 
Determination of differentially expressed transcripts
One-way analysis of variance analysis was performed on the average expression of 29 098 genes across five cell lines including those of parental K562 cell lines. The most variable 3000 transcripts were chosen and hierarchical clustering via average linking was performed using custom software, Cluster and Treeview (http://rana.lbl.gov/EisenSoftware.htm).
14 To determine whether a transcript is up-or downregulated in resistant sublines, the expression change compared to sensitive parental control was measured by calculating the relative difference, r. 
Identification of transcripts with dose-dependent expression change
To identify genes whose expression changes in dose-dependent manner in resistant sublines, we combined two statistical approaches. 15 First, five mean expression levels of control and four resistant sublines were considered as continuum corresponding to imatinib dose increment from 200 to 800 nM. The significance level of up-and downprogression was determined under the alternative hypotheses, H 1 : m cont pm 200 nM pm 400 nM pm 600 nM pm 800 nM or the vice versa, H 1 : m cont X m 200 nM Xm 400 nM Xm 600 nM Xm 800 nM , respectively. We used Bartholomew's homogeneity law for ordered alternatives, and modified F-statistics for comparison of more than two groups. 16 Multiple testing adjustment was performed using Q-value package (http://faculty.washington.edu/~jstorey/qvalue/) that converts obtained P-value into q-value based on false discovery rate methods. 17 The transcripts significant (qo0.05) for up-and downprogression were further tested for the significance in 600 and 800 nM t-tests with Welch correction and examined to be coordinately changed across resistant sublines. Detailed description with used parameters is available in Supplementary note 1.
Gene set enrichment analysis
Functionally related genes were retrieved from public gene database: Gene Ontology, BioCarta (http://www.biocarta.com), KEGG (Kyoto Encyclopedia of Genes and Genomes) and GenMAPP (Gene MicroArray Pathway Profiler). [18] [19] [20] According to gene-versus-annotation matches, genes were categorized into annotation-specified gene sets. A total of 3774 gene sets were collected, whose members have a common functional annotation and are not necessarily exclusive. Enrichment analysis was performed using parametrical analysis of gene enrichment that directly calculates the significance of enrichment based on Z-statistics. 21 To perform enrichment analysis, we further restricted initial gene sets into 721 sets containing at least 10 genes in minimal gene set. 21 We used two kinds of parametrical values, relative difference r.d. and F k to calculate the significance level based on Z-statistics. Total six enrichment analyses were performed using four sets of r.d. representing comparisons between four resistant sublines and control K562 and two sets of F k representing up-and downprogression. We determined activated gene sets when they are significantly enriched in top r.d. for both comparisons of 600 and 800 nM and also in top F k in upprogression and vice versa for repressed gene sets.
Real-time quantitative PCR assay
Total RNA from blood samples of six CML patients before and after acquiring imatinib-resistance (kindly donated from Korean Leukemia Cell and Gene Bank) was used for real-time quantitative PCR (QPCR) analysis for six candidate genes; CASP4, TNFRF21, RAB11A, IGF1, LYN and RHOA. Three of the patients have BCR-ABL mutation and the other three have no mutation. The first-strand cDNA was synthesized using Moloney-murine leukemia virus Reverse Transcriptase (Invitrogen, USA) and used for PCR. Real-time QPCR was performed using Mx3000P QPCR system with software MxPro Version 3.00 (Stratagene, La Jolla, CA, USA). The real-time QPCR mixture of 20 ml contains 10 ng of cDNA, 1 Â SYBR Green Tbr polymerase mixture (FINNZYMES, Finland), 0.5 Â ROX and primers of 20 pmol. GAPDH was used as an internal control in each procedure. The thermal cycling was as follows: 10 min at 951C, followed by 40 cycles of 10 s at 941C, 30 s at 55-601C and 30 s at 721C. To verify specific amplification, melting curve analysis was performed (55-951C, 0.51C/s). Relative quantification was performed by the DDC T method. 22 The sequence information of primers used for real-time QPCR is available in Supplementary note 2.
Results
Expression profile of imatinib-resistant K562 sublines
Four imatinib-resistant K562 sublines are denoted as KR 200 nM , KR 400 nM , KR 600 nM and KR 800 nM according to the imatinib doses used to establish the corresponding sublines. We first examined whether or not the imatinib-resistance of the sublines was owing to the increased transcription or from a point mutation of the BCR-ABL kinase domain, which were commonly reported in previous studies. 4 Neither a point mutation at the known hot spots in the kinase domain nor transcriptional upregulation of the BCR-ABL gene was observed in the four resistant sublines (data not shown). Then, the expression profiles of the K562 and imatinib-resistant sublines were examined using an oligomicroarray encompassing B30 000 human genes. Unsupervised clustering of the 3000 most variable transcripts discriminated the sublines by imatinib dosage used to induce resistance ( Figure 1 ). According to the clustering, the expression profiles of the high-dose groups (KR 600 nM and KR 800 nM ) were distinguished from those of the low-dose groups (KR 200 nM and KR 400 nM ) and parental K562.
Identification of transcripts universally changed across resistant sublines
The transcripts universally up-or downregulated in all four resistant sublines relative to the K562 control were first investigated. Using the relative difference of 74 r.d. as cutoff, 16 and 11 universally changed transcripts were found to be over-or underexpressed (Table 1) . Apoptosis-related genes such as CASP4, TNFRSF21 and TNFRSF9 were universally upregulated in the resistant sublines. The transcription and signaltransduction-associated genes, NOTCH2, SQSTM1 and TGIF, were also upregulated. In case of NOTCH2, its product is positive regulator of renin-angiotensin system (RAS) signal transduction in leukemogenesis and has been implicated in the molecular cross-talk with the mitogen-activated protein (MAP) kinase. 23, 24 Transforming growth factor-b induced factor (TGIF) is the transcriptional co-repressor forming a negative feedback loop in transforming growth factor (TGF)-b signaling. Among the downregulated genes in the resistant sublines, IGF1 and PLCD1 were found to be associated with signal transduction. IGF1 encodes a growth factor that regulates somatic growth and development as well as tumorigenesis. 25 Phospholiphase C, delta 1 (PLCD1) is involved in signal transduction by producing the second messenger molecules, diacylglycerol and inositol-1,4,5-trisphosphate. 26 Cell-cycle-associated molecules such as CCNB1P1 were identified and found to function in the progression of the cell cycle through the G2/M phase. 27 
Expression changes correlated with imatinib doses in resistant sublines
Secondly, genes that showed dose-response pattern between expression and imatinib dosage across the four resistant sublines were investigated (Table 2 ). Figure 2 illustrates the expression pattern of up-and downprogression across the sublines. Of the 22 genes showing a positive correlation with the increasing imatinib dosage, four transcription-related genes were identified, NMI, FOXO3A, ZNF226 and ZNF140. The NMI-encoded protein interacts with transcription factors such as N-MYC, C-MYC and the signal transducer and activator of transcription. In addition, a high expression of the NMI-encoded protein has been demonstrated in myeloid leukemia. 28 As a signaltransduction-related transcript, latent TGF-b binding protein-1 is involved in the TGF-b signaling pathway by producing a protein that interacts with the TGF-b molecules. One putative ATPdependent drug transporter, ABCA8, is also identified among the genes whose expression changes showed positive correlation with imatinib dosage. 29 Cell proliferation-associated genes were identified in the transcripts that showed negative correlation with imatinib dosage. Of these, translocation of myeloid leukemia factor 1 (MLF1) has been frequently observed in myelodysplastic syndrome and acute myeloid leukemia. 30 Among the metabolism and signal transduction-related genes, RAB11A is a RAS-related GTP-binding protein with putative roles in the tumorigenesis. 31 
Gene set enrichment analysis
Gene set enrichment analysis was used to identify the imatinibresistance-associated gene sets by measuring the statistical significance of the enrichment for B700 functionally annotated gene sets. Figure 1 Hierarchical clustering of the imatinib-resistant K562 sublines according to the expression profiles. The top 3000 variable transcripts in the five samples were selected and analyzed using the hierarchical clustering method. In the dendrogram, low-dose resistant sublines (KR 200 nM and KR 400 nM ) along with the parental K562 were distinguished from those of the high-dose group (KR 600 nM and KR 800 nM ).
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Expression profile in primary CML cases
To verify whether the expression changes accompanied by the acquisition of imatinib-resistance in in vitro model are relevant in primary CML cases, six CML patients showing imatinibresistance were analyzed. Log 2 ratio of gene expression values before versus after acquisition of resistance was calculated for the six patients with (n ¼ 3) or without the BCR-ABL mutation (n ¼ 3) (Figure 3 ). Expression ratio of K562 versus KR 800 nM was also demonstrated as reference. CASP4 and TNFRSF21 were upregulated after the acquisition of imatinib-resistance in four and three of the six patients, respectively. However, the expression ratio was not distinctively different between BCR-ABL mutation-positive and -negative patients. For underexpression, RAB11A and IGF1 were consistently downregulated in BCR-ABL mutation-negative cases, whereas upregulated in two of the three BCR-ABL mutation-positive cases. LYN and RHOA, whose upregulation was previously reported to be related with the imatinb-resistance, were also investigated. Although they were up-regulated in a BCR-ABL mutation-negative cell line model, 6, 12 underexpression was observed in two of three BCR-ABL mutation-negative cases in this study. Rather, the expression of LYN and RHOA was significantly upregulated in two of three mutation-positive cases. However, the statistical power was not strong enough owing to the limited number of clinical samples. Further analysis with more patients will be required to validate the result of this study.
Discussion
The aim of this study was to identify gene expression signatures associated with imatinib-resistance by global gene expression analyses on a series of imatinib-resistant K562 sublines. By Table 2 Genes whose expression changes are correlated with imatinib doses across resistant sublines fitting the serial expression profiles of four resistant sublines into the analyses, it was possible to perform a more detailed statistical analysis that is not feasible by simple dichotomous comparison of sensitive versus resistant lines. 11, 12 Clear discrimination of the expression profiles between the low-and high-dose resistant sublines by unsupervised clustering supports the existence of heterogeneous genetic mechanisms in our imatinib-resistant K562 model.
In single gene approach, the universally observed expression changes shared by all resistant sublines might represent the expression features closely associated with the survival of cells in the presence of imatinib. And observed dose-response relationship between expression and imatinib dosage suggests that transcriptional level of the genes is important in acquiring imatinib-resistance. Among the transcripts identified, three upregulated (VCX, TNFRSF21 and TNFRSF9) and six downregulated (SSX6, ANTXR2, IGF1, ACSM3, CCNB1P1 and C1orf19) genes were identified to have both universal and dose-dependent changes. This finding supports the biological potential of these nine genes to be putative surrogate markers indicating imatinib-resistance. However, in functional aspects, such genes have a wide variety of molecular functions among which the essential ones such as signal transduction or proliferation are difficult to determine. Therefore, a recently developed gene set enrichment analysis, which links the members of the genes to specific molecular pathways, was adopted to ensure the biological implication of our result. 32 The essential signatures whose activation or repression is specific to the imatinib-resistance were identified using enrichment analysis combined with single gene approach.
Most of the activated or repressed gene sets identified in enrichment analysis was associated with basic cellular physiology, reflecting the global metabolic changes in the imatinibresistant sublines. Almost half of the 15 activated gene sets having transcription-related annotations showed that global upregulation of the genes involved in transcription is prevalent in the imatinib-resistant sublines. However, there is not enough evidence to pinpoint the increased global transcriptional activity as key determining factor. 33 Similarly, two apoptosis-related gene sets activated in the resistant sublines are likely to represent the continuing cellular responses to imatinib. As shown in clinical samples, the frequency of upregulation for CASP4 and TNFRFS21 was not significantly different between BCR-ABL mutation-positive and -negative cases, indicating that upregulation of apoptosis is a general response to imatinib both in vitro and in vivo cases. Among the repressed gene sets, there were the protein and energy metabolism-associated gene sets, indicating the imatinib-resistant sublines have a lower protein and energy metabolism. The decreased protein metabolism and energy production might be owing to the dormant status of the resistant sublines, which is one of the putative mechanisms by which BCR-ABL primitive progenitor cells evade imatinibinduced apoptosis. 33 The signal-transduction pathway-associated signature is worth consideration. For TGF-b signaling, TGIF and LTBP were found to be universally upregulated in a dose-dependent manner in the imatinib-resistant sublines examined in this study. A previous study reported that TGF-b transcription was upregulated in the imatinib-resistant KCL-22 cell lines. 11 The roles of the TGF-b pathway in tumorigenesis has been recently highlighted along with its diverse roles such as cellular proliferation and possible tumor promoters. 34, 35 These findings of activation of TGF-b signaling indicate that it plays a key role in the acquisition of imatinib-resistance. The three gene sets associated with the small GTPase signaling pathway were repressed, which is indicative of the specific repression of the pathway in the imatinib-resistant sublines. RAS-MAP kinase signaling is one of major downstream effectors and contributes to the pathogenesis of BCR-ABL kinase. 36 The specific inhibition of the downstream pathway such as RAS signaling, as shown in this study, might be a putative mechanism for leukemic cells to become independent of growth inhibition directed by BCR-ABL kinase.
This study also identified several transcripts, which were significantly up-or downregulated, possibly associated with imatinib-resistance. They have potential to become surrogate markers useful in a clinical evaluation of the imatinb-resistant cases as demonstrated in our study of primary imatinib-resistant cases. IGF1 and RAB11A showed consistent downregulation after the acquisition of imatinib-resistance in BCR-ABL mutation-negative primary cases. This suggests that the measurement of expression level for these candidate genes could be used in the prediction of developing of imatinib-resistance in BCR-ABL mutation-negative patients. In case of LYN and RHOA whose up-regulation was reported in imatinib-resistance cell line model, upregulation was not dominant in our BCR-ABL mutation-negative cases. This indicates that the heterogeneous expression patterns of in vivo cases might not be concordant with the observation of in vitro model. a Annotated function is based on the functional categorization of genes in public gene database and symbols in the parentheses represent the origin of data set: GO -Gene Ontology; B -BioCarta; G -GenMAPP and K -KEGG. b,c Gene sets significantly enriched both for two comparisons of 600 and 800 nM and also significant as direct correlated with imatinib doses are considered as activated while repressed gene sets are determined vice versa.
In conclusion, global expression analysis associated with imatinib-resistant in vitro and primary cases revealed number of genes and gene sets possibly associated with the imatinibresistance. The resistance-associated expression signatures identified in this study would provide a deeper understanding of mechanism for the acquisition of resistance as well as for developing improved diagnostic and therapeutic strategies to deal with imatinib-resistant cases. 
